ranibizumab-eqrn

ranibizumab-eqrn (CIMERLI) is an FDA-listed pharmaceutical active ingredient. Route of administration: injection. Current US regulatory status: approved.

CIMERLI is a marketed brand name for ranibizumab-eqrn. Check FDA Drugs@FDA for the current US label holder and prescribing information.

ranibizumab-eqrn has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.